AvantGuard

Developing your first line of defense for when antibiotics fail

AvantGuard operates in consumer packaged goods based in Ithaca, New York, US, founded in 2018.

Profile

AvantGuard is a venture backed, Cornell University spin-off, IndieBio alum with grant funding from the NIH and NSF, among others, run by an experienced entrepreneur. Our first target is multi-drug resistant Candida auris. Once on your skin, there is no current way to eliminate C. auris and you have a 20% chance of getting an infection that carries a 40% mortality rate in 30 days. We can eliminate C. auris, and are planning a clinical trial with assistance from the Mycoses Study Group – the leaders in the field of antifungal medicine in the US. From that success, we will expand to the $4Bn billion fungal skin infection market and the $5Bn healthcare antiseptic market and eventually create a new standard of care, >$50Bn worth of markets, for the post-antibiotic world since antibiotics are losing their effectiveness.

Within the consumer packaged goods space, the company focuses on its core offering rather than a broad product line.

The business is associated with Ithaca, New York, US.

It is recorded at the SOSV portfolio company stage.

Its team size is recorded as 2-10 employees.

Total disclosed funding stands at about $55K.

Website: www.avantguardinc.com